| Abbreviation | Full name |
| ACE | Angiotensin Converting Enzyme |
| BLA | Biologic Licensing Application |
| CA | Carbonic Anhydrase |
| CBER | Center for Biologics Evaluation and Research |
| CHO | Chinese Hamster Ovary |
| COPD | Chronic Obstructive Pulmonary Disease |
| DBC | Division of Biological Control |
| DNA | Deoxyribonucleic Acid |
| EGRF | Epidermal Growth Factor Receptor |
| ERTs | Enzyme Replacement Therapies |
| FDA | Food and Drug Administration |
| GERD | Gastro‐oesophageal Reflux Disease |
| HTA | Health Technology Assessment |
| ICER | Institute for Clinical and Economic Review |
| IFN | Interferon |
| IgG | Immunoglobulin |
| IL | Interleukin |
| IP | Intellectual Property |
| LSD | Lysosomal Storage Disease |
| mAbs | Monoclonal Antibodies |
| NSCLC | Non‐Small Cell Lung Cancer |
| PD‐1 | Programmed Death‐1 |
| PD‐L1 | Programmed‐Death‐Ligand 1 |
| R&D | Research and Development |
| rDNA | recombinant DNA |
| RNA | Ribonucleic Acid |
| TB | Tuberculosis |
| TNF | Tumor Necrosis Factor |
| SMDs | Small Molecule Drugs |
| US | United States |
